Varenicline is a prescription medication used to help adults quit smoking. Sold under the brand name Chantix, it is the most effective single-drug option for smoking cessation, roughly tripling the odds of staying smoke-free at one year compared to quitting without medication. A standard course of treatment lasts 12 weeks, though a second 12-week course is sometimes recommended to improve long-term success.
How Varenicline Helps You Quit
Nicotine from cigarettes triggers the release of dopamine in the brain, which creates the pleasurable feeling that keeps smokers coming back. Varenicline works on the same brain receptors that nicotine targets, but it does two things at once. First, it partially activates those receptors, releasing enough dopamine to take the edge off cravings and withdrawal symptoms. Second, it physically occupies the receptors so that if you do smoke, nicotine can’t fully latch on. This blunts the satisfaction you’d normally get from a cigarette, making it easier to stay away from them.
This dual action is what sets varenicline apart from other quit-smoking aids. Nicotine replacement therapy (patches, gum, lozenges) simply supplies nicotine in a safer form. Bupropion, another prescription option, works on different brain chemistry altogether. Varenicline is the only medication designed to both ease withdrawal and actively reduce the reward of smoking at the same time.
How Effective Is It?
In clinical trials, about 50% of people taking varenicline were continuously smoke-free during the last four weeks of a 12-week treatment course, compared to roughly 17% on placebo. At six months, the gap held: 49% of the varenicline group remained abstinent versus 14% on placebo. Those are strong numbers for a notoriously difficult behavior change.
Head-to-head comparisons with other cessation aids consistently favor varenicline. Nicotine replacement therapy and bupropion each roughly double your odds of quitting compared to going it alone. Varenicline raises those odds by 2.5 to 3 times. In a direct trial against the nicotine patch, 56% of varenicline users were smoke-free at the end of treatment compared to 43% on the patch. At one year, the advantage narrowed (26% vs. 20%) but persisted. Similarly, two separate trials comparing varenicline to bupropion found significantly higher quit rates with varenicline at both 12 weeks and 6 months, with one trial showing a continued advantage at the one-year mark.
The Treatment Timeline
Varenicline uses a gradual dose increase during the first week to reduce side effects. You start with a lower dose for the first three days, step up for the next four days, then move to the full dose of 1 mg twice daily from day eight onward. Your quit date is typically set for the end of that first week, so the medication has time to build up in your system before you stop smoking.
The full treatment course is 12 weeks. If you’ve successfully quit by the end of that period, your prescriber may recommend a second 12-week course to strengthen your chances of staying smoke-free long term. Taking the medication with food or a full glass of water helps reduce nausea, which is the most common side effect.
Common Side Effects
Nausea is the most frequent complaint, affecting about 30% of people taking the standard dose (compared to 10% on placebo). For most people it’s manageable, especially when taking the pill with food and water. If it persists, a dose reduction is an option.
Other side effects reported more often than placebo include:
- Insomnia (18% vs. 13% on placebo)
- Vivid or unusual dreams (13% vs. 5%)
- Constipation (8% vs. 3%)
- Headache (15% vs. 13%)
- Gas and bloating (6% vs. 3%)
- Vomiting (5% vs. 2%)
The vivid dreams are distinctive enough that people often mention them specifically. They aren’t dangerous, but they can be unsettling. Sleep-related side effects (insomnia, unusual dreams, disrupted sleep) collectively affect a meaningful percentage of users, so it’s worth being prepared for that possibility.
The Neuropsychiatric Safety Question
Varenicline carried its most serious safety concern for years: a boxed warning (the FDA’s strongest label warning) about potential neuropsychiatric effects, including mood changes, agitation, and suicidal thoughts. The FDA first flagged these concerns in 2007 and added the boxed warning in 2009.
That warning was removed in December 2016. The turning point was a large international trial called EAGLES, which specifically tested whether varenicline caused psychiatric or behavioral problems. The trial enrolled over 8,000 smokers, including people with existing psychiatric conditions, and found no significant increase in neuropsychiatric events with varenicline compared to nicotine patches, bupropion, or placebo. This was the evidence the FDA needed to drop the boxed warning.
That said, quitting smoking itself can affect mood and mental health, regardless of which method you use. Nicotine withdrawal commonly causes irritability, anxiety, and depressed mood. These symptoms are part of the quitting process, not necessarily a medication side effect.
Availability and Generic Options
The brand-name version, Chantix, was recalled by Pfizer in 2021 due to elevated levels of a contaminant called nitrosamine found during manufacturing quality checks. That recall affected only the Pfizer product. Generic versions of varenicline from other manufacturers were not affected and remained available throughout the shortage. As of late 2025, both brand-name Chantix and generic varenicline are available.
Generic varenicline is the same active ingredient at the same doses, so switching between brand and generic should not affect how well the medication works. The availability of generics has also made the medication more affordable, removing one barrier that previously kept some smokers from trying it.